药明生物荣膺
2020“中国大学生喜爱雇主” 称号
(*Please scroll down for English news.)
近日，由中国人力资源服务商前程无忧 （51job.com）和大学生应届生求职网（yingjiesheng.com）联合发起的2020“大学生喜爱雇主”名单揭晓。药明生物从大学毕业生关注最高的众多企业之中，荣膺2020“中国大学生喜爱雇主”称号。亚马逊、苹果、阿斯利康、强生、罗氏诊断、玛氏中国、特斯拉、哔哩哔哩等各行业知名企业也榜上有名。
药明生物首席执行官陈智胜博士表示：“我们十分荣幸能够获得'大学生喜爱雇主'荣誉称号，对于一家重视新人培养的公司而言，这是一种巨大肯定。药明生物成立以来，员工总数不断增长，业务增速业界领先。我始终认为，我们的成功正是源自我们拥有最好的人才。我要感谢公司各管理层和人力资源团队，这一奖项也是对他们不断提高组织效能，加速人才发展，助力业务长期发展的认可。作为全球领先的生物制药平台企业，我们致力于吸引最优秀的毕业生，并为他们提供良好的发展环境，最终实现‘让天下没有难做的药，难治的病’的宏伟愿景。”
药明生物人力资源部负责人熊丽女士表示：“首先感谢‘中国大学生喜爱雇主’评委会对药明生物在毕业生培养和发展工作方面的高度肯定。在今年大环境发生变化的情况下，药明生物始终坚持推行与时俱进的人才策略，通过雇主品牌提升组织吸引力，系统性吸纳和培养年轻人，为他们提供相互尊重、激情工作和快速发展的工作环境。今年，我们全新的雇主品牌主张是：赋能全球客户，成就良医妙药。希望更多优秀的学子加入我们，成为自豪的药明生物人。”
评选机构通过在全国范围内50余所重点院校与应届生求职网的网上应届毕业生求职满意度调查，在大学生雇主的共计八个维度上，包括：雇主品牌在校园的影响力、利于年轻人才发展和发挥企业文化和企业社会责任承担、领先的薪酬和福利水平、高效、有特色的毕业生培养计划和创新的职业发展计划、与高校保持良好的合作关系，在高校开展丰富活动、课程合作和科研合作、有特色的校园招聘流程和选拔标准，企业高管参加校园招聘、每年提供一定数量和质量的高校毕业生工作和实习机会，进行对比分析。最终在全国范围内甄选出百家“中国大学生喜爱雇主”。
药明生物校园招聘自2011年创立伊始，历经近10个年头，毕业生招聘量呈逐年持续递增势态，先后共吸纳四千余名应届毕业生，与100多所国内外院校建了校企合作关系。各大院校的毕业生可通过药明生物应届生校园招聘项目，加入药明生物并在这里得到充分的成长和发展。
“种子计划”是为公司未来发展培养新人，成为公司未来关键骨干的人才培养项目。加入这个计划之后，就有机会至少参加3~6个月的实习，通过这些全面的系统化培训，学生们可以更快地学习和工作相关的实用技能，并了解并体会公司文化，以更好地适应未来的工作。
“精英计划”是为了培养高层次未来管理者的管理培训生项目。以海内外顶尖院校的高学历精英为目标，“精英计划”通过精心规划的轮岗安排，迅速培养在项目管理、生产管理、平台技术、研发技术、质量管理上的技术能力。优秀的学员还有机会在项目中实践团队管理，修炼管理技能。
目前药明生物的应届毕业生活跃在公司各个关键岗位上，支撑了公司快速发展的需求，助力药明生物业务增速长期保持业界领先。
可以预见的是，国家未来对生物制药行业将越来越重视，药明生物已经是全球领先的开放式、一体化生物制药能力和技术赋能平台，欢迎更多有志于在生物制药行业发展的同学们，加入药明生物，与药明生物一起成长，共同赋能全球客户，成就良医妙药。
相关阅读
|
1 |
|
|
2 |
|
中国大学生喜爱雇主
“中国大学生喜爱雇主” (Top Graduate Employers)由中国最大的人力资源服务商前程无忧 （51job.com）和拥有最多大学生用户的应届生求职网（yingjiesheng.com）联合发起，评选深受校园学子赞赏的最佳雇主。它们多年有计划、持续地招聘中国高校毕业生，在校园开展各种活动和科研项目，帮助和扶持大学生自发的公益活动和创业，它们不仅以吸引优秀学子为目标，也热心帮助中国大学生提升知识技能和全球视野，在学生中有广泛的认知和较高的美誉度。
关于药明生物
药明生物（股票代码：2269.HK）作为一家香港上市公司，是全球领先的开放式、一体化生物制药能力和技术赋能平台。公司为全球生物制药公司和生物技术公司提供全方位的端到端研发服务，帮助任何人、任何公司发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。截至2019年12月31日，在药明生物平台上研发的综合项目达250个，包括121个处于临床前研究阶段，112个在临床早期（I期，II期），16个在后期临床（III期）以及1个在商业化生产阶段。预计到2022 年之后，公司在中国、爱尔兰、美国、德国和新加坡规划的生物制药生产基地合计产能约28万升，这将有力确保公司通过健全强大的全球供应链网络为客户提供符合全球质量标准的生物药。如需更多信息，请访问：
www.wuxibiologics.com.cn。
WuXi Biologics Selected as
Winner of the 2020 Top Graduate Employers Award in China
The Top Graduate Employers is co-launched by 51job.com, the leading integrated human resources service provider in China, and yingjiesheng.com, the leading online job search portal for college users in China. The list of 2020 Top Graduate Employers Award has recently been announced. WuXi Biologics stood out alongside top companies as the winner of the Top Graduate Employers Award. Other winning employers include Amazon, Apple, AstraZeneca, Bilibili, Johnson & Johnson, Mars China, Roche Diagnosis, Tesla and other industry leaders.
Since the inception of WuXi Biologics, the total number of our employees continues to grow and the business growth is leading in the industry. I always believe that the secret of our success is our outstanding talents." said Dr. Chris Chen, Chief Executive Officer of WuXi Biologics. "I would like to thank all the leadership team and our HR for their contributions to continuously enhance organization productivity and accelerate talent development to support the long-term development of our business. As a leading global open-access biologics technology platform, WuXi Biologics is committed to attracting excellent graduates by providing them with a good development environment to realize our vision of 'Every drug can be made and every disease can be treated'."
"First, I'd like to thank the Award Committee for their recognition for our efforts in cultivating and developing graduates at WuXi Biologics." said Lily Xiong, Head of Human Resources Department at WuXi Biologics. "Despite the unprecedented global pandemic, WuXi Biologics continues to implement our talent strategies and enhance company's attractiveness through maintaining a good employer brand. We also set up systematic plans to attract and train talents and made great contributions to create a good working environment for employees to gain respect, passion and rapid development. Our employer brand proposition of 2020 is 'To Empower Global Customers and Create Great Cures'. I hope more outstanding graduates can join us and become proud bioneers."
The Award Committee has conducted online surveys to measure the job-search satisfaction of fresh graduates of more than 50 leading universities in China. It assesses and identifies the Top Graduate Employers based on 8 criteria, and also compares and analyzes the data from candidate companies in the same industry. Finally, one hundred Top Graduate Employers will be selected nationwide.
It has been ten years since the establishment of WuXi Biologics Campus Recruitment Program in 2011. The number of graduates has been increasing year by year. The Company has attracted more than 4,000 fresh graduates and established school-enterprise partnerships with more than 100 domestic and overseas universities. Graduates from various universities can join in WuXi Biologics and get full growth and development through the Program.
The Seeds Program is a talent training program to develop new talents for the future development of WuXi Biologics and help them become the key talents of the Company in the future. After joining the program, students have the opportunity to participate in an internship for at least 3 to 6 months. Through these comprehensive and systematic training, students can learn practical job-related skills more quickly and understand the Company culture to better adapt to future jobs.
The Elite Program is a management trainee program designed to develop high-level future managers. Aiming at the highly educated elites from the top universities at home and abroad, the Program rapidly cultivates their technical abilities in project management, production management, platform technology, R&D technology and quality management through the carefully planned job rotation arrangement. Excellent students also have the opportunity to practice team management and develop management skills.
Over the years, our graduates have been active in various key positions of WuXi Biologics, supporting the Company's rapid development and long-term business growth. It is expected that Chinese government will pay more attention to the biopharmaceutical industry in the future. WuXi Biologics is a leading global open-access and integrated capability and technology enabling platform. We WuXi Biologics welcome students who are interested in biopharmaceutical to join us, grow together with the Company, Empower Global Customers, and Create Great Cures.
Top Graduate Employers
The “Top Graduate Employers” is co-launched by 51job.com, the leading integrated human resources service provider in China, and yingjiesheng.com, the leading online job search portal for college users in China. The award is being presented to the companies who have a long-term campus recruitment plan as a vital part of their human resource strategy. These companies have recruited college graduates for many years, supported dynamic events and research programs on campus, sponsored activities and nurtured entrepreneurship, and earned broad recognition and high reputation among students.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and strong value proposition to our global clients. As of December 31, 2019, there were a total of 250 integrated projects, including 121 projects in pre-clinical development stage, 112 projects in early-phase (phase I and II) clinical development, 16 projects in late-phase (phase III) development and one project in commercial manufacturing. With total estimated capacity for biopharmaceutical production planned in China, Ireland, the U.S., Germany and Singapore exceeding 280,000 liters by 2022, we will provide our biomanufacturing partners with a robust and premier-quality global supply chain network. For more information on WuXi Biologics, please visit www.wuxibiologics.com.
媒体联系 Media Contact：
药明生物 WuXi Biologics
黄可博士 Kevin Huang PhD
+86-510-85353705
kevin_huang@wuxibiologics.com
注：本信息不构成药明生物的信息披露或投资建议
